Disabling critical ‘node’ revs up attack when cancer immunotherapies fall short
PHILADELPHIA--An existing drug known as a JAK inhibitor may help patients who don't respond to the so-called checkpoint inhibitor immunotherapy drugs overcome that resistance, suggests...






